Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06999590 · ClinicalTrials.gov registry record · Phase 4
Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers
A Phase 4 study of Ulcer and Pressure Ulcer, sponsored by Tiger Biosciences.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT06999590: Recruiting Phase 4 study of Ulcer and Pressure Ulcer, sponsored by Tiger Biosciences.
NCT06999590 is a Phase 4 study of Ulcer and Pressure Ulcer that is actively recruiting participants, run by Tiger Biosciences. The registered enrollment target is 500 participants, above the 178-participant average among 13 other Ulcer trials with a reported enrollment target (181% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06999590, a Phase 4 study of Ulcer and Pressure Ulcer, is actively recruiting participants, sponsored by Tiger Biosciences.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study it to evaluate several cellular, acellular, and matrix-like products (CAMPs) and standard of care versus matched standard of care controls in the management of nonhealing pressure ulcers.
Primary Outcome
To determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing pressure ulcers with multiple CAMPs plus SOC versus matched SOC controls (mSOC) over 20 weeks using a modified platform trial design.
Conditions Studied
Interventions
- OTHER Standard of Care
- OTHER ACApatch™
- OTHER caregraFT™
Study Locations (1)
Pennsylvania
- Serena Group - Monroeville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2027-05 |
| Phase | Phase 4 |
What NCT06999590 shows while recruiting
NCT06999590 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 178-participant average among 13 other Ulcer trials with a reported enrollment target (181% higher).
The record links to 4 conditions, with Ulcer appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.
NCT06999590 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06999590 about?
NCT06999590 is a clinical study titled "Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers". The purpose of this study it to evaluate several cellular, acellular, and matrix-like products (CAMPs) and standard of care versus matched standard of care controls in the management of nonhealing pressure ulcers.
What is the current status of trial NCT06999590?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2025-05-20. Estimated completion is 2027-05.
What conditions does trial NCT06999590 study?
This clinical trial studies the following conditions: Ulcer, Pressure Ulcer, Pressure Injury, Ulcer, Pressure.
What interventions are being tested in trial NCT06999590?
The interventions under investigation include: Standard of Care (OTHER), ACApatch™ (OTHER), caregraFT™ (OTHER).
Who is sponsoring clinical trial NCT06999590?
This trial is sponsored by Tiger Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06999590 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06999590's enrollment target sits among peer trials
500 2nd of 13 the highest of 13 other Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy
RECRUITING · Phase 4
-
Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
RECRUITING · Phase 4
-
A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.
RECRUITING · Phase 4
-
Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.
RECRUITING · Phase 4
-
Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.
RECRUITING
-
Total Contact Soft Cast in Diabetic Foot Ulcers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI